Segment Reporting (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)
Segment Reporting [Abstract]
Number of operating segments | Segment									1
Number of reportable segments | Segment									1
Segment Expenses [Abstract]
Loss from operations									$ (36,321,195)	$ (43,045,234)
Interest income									2,514,816	2,902,939
Total operating expenses									36,321,195	43,045,234
Interest expense									(4,673,174)	(4,205,922)
Loss before income taxes									(38,479,553)	(44,348,217)
Benefit from income taxes									869,169	1,406,019
Net loss	$ (7,952,352)	$ (10,726,658)	$ (8,327,897)	$ (10,603,477)	$ (10,898,216)	$ (10,849,169)	$ (11,534,895)	$ (9,659,918)	(37,610,384)	(42,942,198)
Comprehensive loss									(37,610,384)	(42,942,198)
Operating Segment [Member] | PDS [Member]
Segment Expenses [Abstract]
Salaries and benefits									15,282,537	16,979,251
Professional fees									4,819,562	5,530,998
General administrative expenses									1,438,833	1,689,772
Clinical development expenses									8,299,589	12,055,623
Other development expenses									6,480,674	6,789,590
Total operating expenses									36,321,195	43,045,234
Net loss									(37,610,384)	(42,942,198)
Reconciling Item [Member]
Segment Expenses [Abstract]
Interest income									2,514,816	2,902,939
Interest expense									(4,673,174)	(4,205,922)
Benefit from income taxes									$ 869,169	$ 1,406,019